- Home
- IRWD vs GALT Comparison
IRWD vs GALT Comparison
Compare IRWD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRWD
- GALT
- Stock Information
- Founded
- IRWD 1998
- GALT 2000
- Country
- IRWD United States
- GALT United States
- Employees
- IRWD N/A
- GALT N/A
- Industry
- IRWD Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- IRWD Health Care
- GALT Health Care
- Exchange
- IRWD Nasdaq
- GALT Nasdaq
- Market Cap
- IRWD 251.8M
- GALT 232.3M
- IPO Year
- IRWD 2010
- GALT N/A
- Fundamental
- Price
- IRWD $3.11
- GALT $6.25
- Analyst Decision
- IRWD Buy
- GALT Strong Buy
- Analyst Count
- IRWD 5
- GALT 3
- Target Price
- IRWD $5.34
- GALT $6.00
- AVG Volume (30 Days)
- IRWD 3.2M
- GALT 432.8K
- Earning Date
- IRWD 11-10-2025
- GALT 11-14-2025
- Dividend Yield
- IRWD N/A
- GALT N/A
- EPS Growth
- IRWD N/A
- GALT N/A
- EPS
- IRWD 0.18
- GALT N/A
- Revenue
- IRWD $338,987,000.00
- GALT N/A
- Revenue This Year
- IRWD N/A
- GALT N/A
- Revenue Next Year
- IRWD N/A
- GALT N/A
- P/E Ratio
- IRWD $17.56
- GALT N/A
- Revenue Growth
- IRWD N/A
- GALT N/A
- 52 Week Low
- IRWD $0.53
- GALT $0.73
- 52 Week High
- IRWD $5.13
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- IRWD 74.04
- GALT 66.51
- Support Level
- IRWD $1.88
- GALT $5.10
- Resistance Level
- IRWD $3.47
- GALT $6.15
- Average True Range (ATR)
- IRWD 0.33
- GALT 0.55
- MACD
- IRWD 0.12
- GALT 0.04
- Stochastic Oscillator
- IRWD 79.56
- GALT 97.28
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.